Hodgkin lymphoma (HL) is a treatable cancer with an incidence peak in adolescent and young adult years. Treatment strategies have been developed to balance the intensity of therapy needed to maintain ...

The decision to use newer agents in relapsed/refractory follicular lymphoma is heavily influenced by the disease’s inherent ...

Pamela Jones, DVM, DACVIM (Oncology), explains why lymphoma isn’t one disease and how phenotyping, client goals, and teamwork guide individualized treatment.

The immune system produces immune cells that travel through the lymphatic system to fight off infections and diseases. T-cell lymphoma is a type of blood cancer that affects specific immune cells ...

These results suggest a correlation between dose intensity and disease control. Thus, it is possible that further dose-intensification of the conditioning regimen may improve outcome of patients ...

Israeli researchers at a blood cancer conference in the US reported a lymphoma treatment that can achieve 100% survival rates ...

R 2 is the only second-line alternative to chemoimmunotherapy-based treatment for patients with relapsed/refractory ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify ...

Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in ...

Jones anchored her discussion in a core philosophy for veterinary oncology: "one size does not fit all.” According to Jones, ...